NCT02507570 - Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2015

Primary Completion Date

January 18, 2019

Study Completion Date

January 18, 2019

Conditions

Prostate Carcinoma Metastatic to the Bone

Interventions

DRUG

Enzalutamide

used concomitantly

RADIATION

Radium ra 223 dichloride

Trial Locations (4)

Associated Medical Professionals, Syracuse

Chesapeake Urology Research Associates, Towson

Urology of Virginia, PLLC, Virginia Beach

Carolina Urologic Research Center, Myrtle Beach